| Literature DB >> 31200434 |
Tamara Alhambra-Borrás1, Estrella Durá-Ferrandis2, Maite Ferrando-García3.
Abstract
This study analyses the effectiveness and cost-effectiveness of a group-based multicomponent physical exercise programme aimed at reducing the risk of falling and frailty in community-dwelling older adults. This is a pretest-posttest non-equivalent control group design, with an intervention group and a comparison group. Participants were evaluated at baseline and after 9 months. The effectiveness analyses showed significant reduction in the risk of falling (-45.5%; p = 0.000) and frailty (-31%; p = 0.000) after the intervention for the participants in the physical exercise programme. Moreover, these participants showed an improvement in limitations in activities of daily living, self-care ability and the use of health resources, physical performance, balance and body mass index. The cost-effectiveness analyses showed that the intervention was cost-saving and more effective than usual care scenario. A novel group-based multicomponent physical exercise programme showed to be more effective and cost-effective than usual care for older adults suffering from risk of falling and frailty.Entities:
Keywords: ageing; falls; frailty; older adults; physical exercise; risk of falling
Mesh:
Year: 2019 PMID: 31200434 PMCID: PMC6617042 DOI: 10.3390/ijerph16122086
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Flow of participants through the study. a Inclusion criteria: Having risk of falling and/or frailty and, for intervention group, acceptance to participate in the physical exercise programme. * Experimental mortality includes the participants who dropped out of the study after having met the inclusion criteria.
Intragroup and intergroup differences of risk of falling *.
| Risk of Falling Differences | Intervention Group | Comparison Group | Intergroup Differences |
|---|---|---|---|
|
| 50 (90.9%) | 86 (63.2%) | X2 = 14.628; |
|
| 25 (45.4%) | 87 (64.0%) | X2 = 5.536; |
|
| −45.5% | +0.8% | |
|
| McNemar; | McNemar; | |
|
| 0.29 | 0.38 |
* Intragroup differences were analysed using McNemar test and intergroup analyses using Chi-square test. ** Effect size effect was calculated using Cramer’s V (small effect = 0.2, medium effect = 0.5, large effect = 0.8).
Intragroup and intergroup differences of frailty *.
| Frailty Differences | Intervention Group | Comparison Group | Intergroup Differences |
|---|---|---|---|
|
| 6.20 ± 3.15 | 5.21 ± 2.24 | U de Mann–Whitney = 3031.5; |
|
| 4.27 ± 2.69 | 5.01 ± 2.26 | U de Mann–Whitney = 3054.5; |
|
| −31% | −4% | |
|
| Wilcoxon z = −4.373; | Wilcoxon z = −1.142; | |
|
| 0.59 | 0.09 |
* Intragroup differences were analysed using Wilcoxon’s signed rank test and intergroup differences using Mann–Whitney U test. ** Effect size effect was calculated using r = Z/√N (r: effect size; Z: z value from Wilcoxon test; N: Observation number; small effect = 0.2, medium effect = 0.5, large effect = 0.8). Alternative to Cohen’s d when general assumptions of Cohen’s formula are violated (Rosenthal, 1994).
Intragroup differences (intervention group only) of physical performance and body composition *.
| Physical Performance and Body Composition Variables | PRE | POST | Pre-Post Difference | Effect Size ** |
|---|---|---|---|---|
|
| ||||
| | 7.71 ± 2.07 | 8.35 ± 2.15 | 0.35 | |
| | 3.18 ± 0.98 | 3.51 ± 0.84 | 0.35 | |
| | 2.44 ± 1.03 | 2.62 ± 1.01 | 0.18 | |
| | 2.09 ± 1.06 | 2.22 ± 1.17 | 0.16 | |
|
| ||||
| | 70.95 ± 14.02 | 70.39 ± 13.9 | 0.07 | |
| | 30.96 ± 6.07 | 30.55 ± 5.95 | 0.07 | |
| | 27.61 ± 10.07 | 26.95 ± 9.87 | 0.04 | |
| | 43.34 ± 6.66 | 42.72 ± 8.52 | 0.01 | |
| | 31.95 ± 4.78 | 31.82 ± 4.95 | 0.02 |
* Intragroup differences were analysed using T-test and Wilcoxon’s signed rank test. ** Effect size was calculated using Cohen’s d for Weight, BMI and Body fat (small effect = 0.2, medium effect = 0.5, large effect = 0.8); the effect size for the other variables was calculated using r = Z/√N (r: effect size; Z: z value from Wilcoxon test; N: Observation number; small effect = 0.2, medium effect = 0.5, large effect = 0.8). SPPB: Short Physical Performance Battery.
Intragroup differences of health-related variables *.
| Health-Related Variables | Intervention Group | Comparison Group | |
|---|---|---|---|
|
| % of change | +7% | −9% |
| Intragroup difference | |||
| Effect size ** | 0.17 | 0.28 | |
|
| % of change | −2% | −7% |
| intragroup difference | |||
| Effect size ** | 0.08 |
| |
|
| % of change | +7% | +8% |
| Intragroup difference | |||
| Effect size ** | 0.48 | 0.42 | |
|
| % of change | −6% | +3% |
| Intragroup difference | |||
| Effect size ** | 0.35 | 0.01 | |
|
| % of change | −9% | +4% |
| Intragroup difference | |||
| Effect size ** | 0.22 | 0.09 | |
|
| % of change | −33% | −7% |
| Intragroup difference | |||
| Effect size ** | 0.48 | 0.15 | |
|
| % of change | −50% | +14% |
| Intragroup difference | |||
| Effect size ** | 0.08 | 0.18 | |
* Intragroup differences were analysed using Wilcoxon’s signed rank test and McNemar test. ** Effect size were calculated using r = Z/√N (r: effect size; Z: z value from Wilcoxon test; N: Observation number; r can be interpreted as small effect = 0.1, medium effect = 0.3, large effect = 0.5). The effect size of hospitalisation was calculated using phi from McNemar test (Phi can be interpreted as small effect = 0.1, medium effect = 0.3, large effect = 0.5). ADLS: activities of daily living.
Input data used to populate the Monitoring and Assessment Framework for the European Innovation Partnership on Active and Healthy Ageing (MAFEIP) model.
| Variables Used in MAFEIP | Intervention Group | Comparison Group |
|---|---|---|
|
| ||
| Recurring cost per patient/year (intervention) | 104€ | - |
|
| ||
| Baseline state * | 0.81 | 0.81 |
* Baseline state includes those participants who show an improvement in the risk of falls and/or frailty at the final evaluation and Deteriorated state includes those participants showing a worsening in the risk of falling and/or frailty or those that show no progression (after 9 months remain the same). ** Utility is the quality of life weight (utility of 1 would refer to the quality of life in perfect health and a utility of 0 would refer to no quality or dead).
Figure 2Incremental cost by age (healthcare). Figure 2 presents incremental costs for every age-gender combination in the specified target population. * Undiscounted incremental costs are those not applying the discount factors for costs and effects which are used to estimate outcomes while taking into account the future costs and health effects. This means adjusting for differences in the timing of costs (estimated expenditure) compared to health benefits (outcomes). The discount factor rate applied to this study was 3.5% for both cost and outcomes.
Figure 3Incremental effects by age. Figure 3 presents incremental effects for every age-gender combination in the specified target population.
Incremental costs and health-related quality of life (HRQoL) effects (cost-effectiveness).
| Incremental Cost and HRQoL * Effects | Effect Result |
|---|---|
| Incremental cost (healthcare) | −44,832.92 |
| Incremental effects | 0.513 |
| Incremental cost-effectiveness ratio (healthcare) | Dominant |
* HRQoL: health-related quality of life.
Figure 4Cost-effectiveness plane (healthcare costs). Figure 4 presents the overall impact of the intervention on the costs and effects of the whole target population ICER: incremental cost-effectiveness ratio; WTP Threshold: willingness to pay (WTP) threshold per quality-adjusted life-year (QALY).